Regulus Therapeutics drug farabursen is a potential first-in-class treatment for a rare kidney disease whose only FDA-approved therapy introduces severe toxicity risks. Farabursen is joining a Novartis drug lineup spanning several therapies for rare renal disorders.
“We showed that cancer stem cells co-opt an RNA editing system to clone themselves. What’s more, we found a method to dial it down,” said principal investigator Dr. Catriona Jamieson, of UC San Diego School of Medicine.
Explore top PTSD treatment centers in Arizona, offering personalized care, holistic therapies and expert support to help individuals heal and reclaim their lives.
Diagnostics startup Miroculus became a bit of a media darling last fall, in part from its TED Talk on bringing inexpensive, rapid-fire cancer diagnostics to the developing world. The Bay Area startup just raised the first, $2.3 million tranche of a $3.6 million seed round, raised from a mixture of angel and venture investors, CEO Alejandro […]